News

27 Sep 2017

Article by Dr David Bunton (co-authored) in the European Pharmaceutical Review, Autumn 2017

REPROCELL Europe Ltd’s CEO, Dr David Bunton, has co-authored an article titled New Strategy that has been published in the European Pharmaceutical Review, Autumn 2017. The article is in the EPR’s section, Applied Research, Development and Production. It is co-authored by David Bunton at REPROCELL Europe, Marian McNeil at Stratified Medicine Scotland and Pamela Brankin at Aridhia.
Read More >>

15 Sep 2017

Visit REPROCELL Stand H2 at ELRIG Drug Discovery 2017 Conference, 3-4 October 2017

Visit REPROCELL Stand H2 at ELRIG Drug Discovery 2017 Conference, 3-4 October 2017
Read More >>

15 Sep 2017

Visit REPROCELL Booth 107 at the SPS Annual Meeting, Berlin, 24-27 September 2017

Visit REPROCELL Booth 107 at the SPS Annual Meeting, Berlin, 24-27 September 2017
Read More >>

06 Sep 2017

Visit REPROCELL Booth A66 at Basel Life Science Week (MipTec), 11-13 September 2017

Basel Life Science Week this year will be held at Basel Congress Centre, Switzerland on 11-13 September 2017. REPROCELL will be at booth A66 at the MipTec Vendor Exhibition, located in Hall 4.1.
Read More >>

1 2 3 4 >>

Latest Proteon and Biopta publication demonstrates Proteon's Vonapanitase effects in human cephalic veins

13/05/2016

Proteon Therapeutics Announces Publication in Cardiovascular Pharmacology: Open Access Describing Promising Nonclinical Results for Vonapanitase in Improving Arteriovenous Fistula (AVF) Maturation and patency in Chronic Kidney Disease (CKD) Patients.

Proteon Therapeutics Inc. (Nasdaq:PRTO), a longstanding client of Biopta, is developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. Proteon today announced publication of additional nonclinical data on investigational drug vonapanitase in chronic kidney disease (CKD). The ex vivo study demonstrated that  vonapanitase removed elastic fibres from human cephalic veins in a dose-dependent manner, as assessed by both desmosine and histological staining of elastic fibres.
 
The study, titled Recombinant Human Elastase Treatment of Cephalic Veins, was published in Cardiovascular Pharmacology: Open Access. Proteons Senior Vice President and Chief Medical Officer, Steven Burke, M.D., is the senior author of the published manuscript. Dr Karen Bingham and Dr Emma Moss of Biopta were co-authors. The full paper can be accessed here

Live chat by BoldChat